XML 37 R30.htm IDEA: XBRL DOCUMENT v3.25.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2025
Stockholders' Equity Note [Abstract]  
Schedule of Stock-Based Compensation Expense

The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations (in thousands):

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Cost of revenue

$

394

 

 

$

383

 

 

$

1,054

 

 

$

1,123

 

Research, development and clinical trials
 expenses

 

850

 

 

 

1,077

 

 

 

3,355

 

 

 

3,078

 

Selling, general and administrative expenses

 

7,892

 

 

 

6,484

 

 

 

23,057

 

 

 

18,256

 

 

$

9,136

 

 

$

7,944

 

 

$

27,466

 

 

$

22,457